V4762
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody produced in mouse
clone FLT-19, tissue culture supernatant
Synonyme(s) :
Anti-Flt1 Receptor, Anti-VEGF R-1
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Source biologique
mouse
Conjugué
unconjugated
Forme d'anticorps
tissue culture supernatant
Type de produit anticorps
primary antibodies
Clone
FLT-19, monoclonal
Contient
15 mM sodium azide
Espèces réactives
human
Technique(s)
immunohistochemistry (frozen sections): 1:100 using human placenta
immunoprecipitation (IP): suitable
indirect ELISA: suitable
microarray: suitable
Isotype
IgG1
Numéro d'accès UniProt
Conditions d'expédition
dry ice
Température de stockage
−20°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... FLT1(2321)
Description générale
Monoclonal Anti-VEGF Receptor-1 (Flt1 Receptor) (mouse IgG1 isotype) is derived from the FLT-19 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a recombinant extracellular domain of VEGF Receptor-1 (Flt1 Receptor) of human origin. Vascular endothelial growth factor (VEGF), also called vasculotropin (VAS)1 and vascular permeability factor (VPF) 2 is a member of a family of endothelial cell mitogens and angiogenic factors. VEGF is a homodimeric heparin-binding glycoprotein. VEGF binds to two structurally similar receptor tyrosine kinases; Flt15 (fms-like tyrosine kinase 1, also termed VEGF Receptor-1, VEGF-R1) and KDR6 (kinase-insert domain containing receptor, also termed VEGF-R2). Flt1 is predominately expressed in human placenta and human vascular endothelial cells, while KDR is more widely expressed in all vessel-derived endothelial cells but low in human and fetal bovine placenta.
Mouse monoclonal clone FLT-19 anti-Vascular Endothelial Growth Factor Receptor-1 antibody recognizes the extracellular domain of human VEGF Receptor-1 molecule (Flt1 Receptor). The antibody does not recognize VEGF Receptor-2 (KDR), VEGF receptor-3 (sFlt4,) and PDGF-Rβ.
Immunogène
recombinant human extracellular domain of VEGFR-1.
Application
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody produced in mouse has been used in:
- immunofluorescence labelling
- enzyme-linked immunosorbent assay (ELISA)
- immunohistochemistry
- immunoprecipitation
Mouse monoclonal clone FLT-19 anti-Vascular Endothelial Growth Factor Receptor-1 antibody may be used for the localization of VEGF-R1 using various immunochemical assays such as ELISA, immunoblotting, immunocytochemistry, immunohistochemistry, and immunoprecipitation. Antibodies that react specifically with VEGF receptors are useful for the study of the specific differential tissue expression and intracellular localization of the receptor in normal and neoplastic tissue.
Actions biochimiques/physiologiques
The mitogenic activity of VEGF appears to be stimulated by specific VEGF receptors (160-200 kDa) which can be found on the surface of various endothelial cells. VEGF binds to two structurally similar receptor tyrosine kinases; Flt1 (fms-like tyrosine kinase 1, also known as VEGF Receptor-1 (VEGF-R1), and KDR (kinase insert domain containing receptor, also known as VEGF-R2). Studies using KDR and Flt1 stably transfected endothelial cell lines have shown that these two receptors exhibit different affinities to VEGF and mediate different responses. KDR/Flk1 does not respond to placental growth factor (PlGF), a VEGF related growth factor, while Flt1 binds PlGF specifically. Flt1 is predominately expressed in human placenta and human vascular endothelial cells. Both VEGF receptors (KDR and Flt1) are upregulated in human fetal and adult kidney.
Vascular endothelial growth factor (VEGF) stimulates the proliferation of endothelial cells isolated from both small and large vessels.
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Mention d'avertissement
Warning
Mentions de danger
Conseils de prudence
Classification des risques
STOT RE 2
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 3
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Real-time ligand binding of fluorescent VEGF-A isoforms that discriminate between VEGFR2 and NRP1 in living cells
PeachnCJ, et al.
Cell Chemical Biology, 25(10), 1208- 1218 (2018)
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy
Shinkaruk S, et al.
Current Medicinal Chemistry. Anticancer Agents, 3(2), 95-117 (2003)
M Simon et al.
Journal of the American Society of Nephrology : JASN, 9(6), 1032-1044 (1998-06-11)
Vascular endothelial growth factor (VEGF) has an important function in renal vascular ontogenesis and is constitutively expressed in podocytes of the adult kidney. The ability of VEGF to be chemotactic for monocytes and to increase the activity of collagenase and
A Sawano et al.
Blood, 97(3), 785-791 (2001-02-07)
Flt-1, also known as vascular endothelial growth factor receptor 1 (VEGFR-1), is a high-affinity tyrosine kinase receptor for VEGF and is expressed almost exclusively on vascular endothelial cells. As an exception, Flt-1 transcript was recently found to be expressed in
Chloe J Peach et al.
Cell chemical biology, 25(10), 1208-1218 (2018-07-31)
Fluorescent VEGF-A isoforms have been evaluated for their ability to discriminate between VEGFR2 and NRP1 in real-time ligand binding studies in live cells using BRET. To enable this, we synthesized single-site (N-terminal cysteine) labeled versions of VEGF165a, VEGF165b, and VEGF121a.
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique